Why the study?
Does reducing the dose of enoxaparin to <90% of the FDA-approved dose reduce major bleeding or increase thrombosis in morbidly obese patients weighing ≥120 kg?
Population
462 adults weighing ≥120 kg receiving therapeutic anticoagulation with enoxaparin for >24 hours. Excluded…
Comparison
Enoxaparin dose <90% of the FDA-approved dose… vs Enoxaparin dose ≥90% of the FDA-approved dose…
Design
Cohort
Follow-up
within 7 days of discharge or discontinuation of…
Authors
Loading...
Dose reduction of enoxaparin in patients ≥120 kg was not associated with lower bleeding or higher thrombosis risk; leaves open optimal strategy for prospective trials.
Does reducing the dose of enoxaparin to <90% of the FDA-approved dose reduce major bleeding or increase thrombosis in morbidly obese patients weighing ≥120 kg?
Empiric dose reduction of enoxaparin in morbidly obese patients (≥120 kg) did not significantly reduce major bleeding or increase thrombotic events, suggesting standard weight-based dosing may be reasonable unless other bleeding risk factors are present.
Czupryn et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: